The immune system is made up of trillions of specialised cells (white blood cells) that detect and destroy pathogens or their toxins. Some white blood cells, which are known as lymphocytes, and the antibodies they produce, are highly specific. Each recognises only one pathogen or its toxin. A key feature of lymphocytes is that after an infection, lymphocytes specific to the pathogen will persist in the body. These specific, long-lived lymphocytes are called memory cells. If a person encounters the same pathogen again in the future, these memory cells will help the immune system mount a much quicker, larger and more sustained response that controls the infection more efficiently, often without development of any clinical symptoms.

The immune system’s capacity to have a memory of previous encounters with an infection is the basis for vaccination. Each vaccine contains one or more antigens from a pathogen (i.e. components able to stimulate immunity); types of antigenic material include the killed whole pathogen or components of it, or a live but weakened version of the whole pathogen. The antigens in a vaccine are recognised by lymphocytes and lead to development of memory cells as well as antibodies. If, after successful immunisation with a vaccine, a person is exposed to the actual pathogen, the memory cells enable the immune system to mount a rapid, sustained immune response, thereby greatly reducing the complications associated with a natural infection.

Immunisation with each vaccine protects an individual from a serious infectious disease and from associated long-term complications, which may include chronic organ damage and diseases such as cancer. Decreasing the number of people in the community who are infected with a particular pathogen has a positive impact on individuals who are susceptible to the infection because they are less likely to come into contact with it. This effect is called herd immunity. As a result, several infectious diseases have been controlled or almost eliminated in Australia, which would never have occurred just due to improvements in healthcare, sanitation or nutrition.

Many effective vaccines exist; nevertheless, researchers continue to develop new vaccines for use against infectious diseases for which no effective vaccines are currently available. A critical component of this vaccine development is effectiveness and safety testing. Before release for use in the broad community, a vaccine must undergo a series of rigorous clinical trials, each of which involves a greater number of participants. New and existing vaccines also undergo stringent monitoring once they are in widespread use in the community to ensure their ongoing safety and effectiveness.

Vaccines are the most successful form of disease prevention available, and will continue to be an essential tool in controlling infections and their complications. In the future, vaccines may also be effective in treating and preventing some non-infectious diseases.

This document aims to summarise and clarify the current understanding of the science of immunisation for non-specialist readers. The document is structured around six questions.
1 / What is immunisation?
The purpose of immunisation is to prevent people from acquiring infectious diseases and to protect them against the associated short- and longer-term complications. Immunisation describes the process whereby people are protected against an infection; vaccine refers to the material used for immunisation, while vaccination refers to the act of giving a vaccine to a person. Vaccines work by stimulating the body’s defence mechanisms (immune system) against an infection, helping it to detect and destroy the infection when it is encountered again in the future without development of significant symptoms or complications. See page 4.

2 / What is in a vaccine?
Vaccines generally contain two main types of ingredients: antigens, which are designed to cause the immune system to produce a specific immune response; and adjuvants, which amplify the body’s immune response. See page 8.

3 / Who benefits from vaccines?
In the short term, immunisation protects individuals from a specific infectious disease and its immediate complications. But immunisation may also have long-term protective effects—from cancer and other chronic conditions. An important feature of immunisation is that it also benefits the entire community. When a significant proportion of individuals in a community have become immune to a specific disease through immunisation, people who are still susceptible to the disease are less likely to come into contact with someone who is carrying the causative infectious agent. See page 10.

4 / Are vaccines safe?
Vaccines, like other medicines, can have side effects, but the vaccines in current use in Australia provide benefits that greatly outweigh their risks. The great majority of reactions after vaccination are minor. Some adverse events coincide with vaccination but are not caused by the vaccine. Serious side effects from vaccines are extremely rare. See page 13.

5 / How are vaccines shown to be safe?
Safety research and testing is an essential part of vaccine development and manufacture. Before vaccines are made available, clinical trials with increasing numbers of participants are required to study safety as well as effectiveness. After vaccines have been introduced into the community, safety monitoring continues. See page 16.

6 / What does the future hold for vaccination?
In recent decades, vaccine technology has greatly improved, resulting in the production of better and safer vaccines against an increasing number of infectious diseases. The future of vaccination includes extending the use of existing vaccines, developing new technologies to deliver vaccines and generating new vaccines for both infectious and non-infectious diseases like cancer. See page 18.
DEFINITIONS

Immunisation describes the process whereby people are protected against illness caused by infection with micro-organisms (formally called pathogens).

The term vaccine refers to the material used for immunisation, while vaccination refers to the act of giving a vaccine to a person.

Immunity describes the state of protection that occurs when a person has been vaccinated or has had an infection and recovered.

Vaccination, like infection, confers immunity by interaction with the immune system.

The term micro-organism refers to infectious agents that can only be seen under the microscope and here covers bacteria, viruses, fungi and protozoa.

Antigens are the components/fragments from pathogens or their toxins.

---

Immunisation protects against infectious disease

The purpose of immunisation is to prevent people from acquiring infections and to protect them against the short- and longer-term complications of those infections, which can include chronic illnesses, such as cancer, and death.

Vaccines work by stimulating the body’s defence mechanisms against infection. These defence mechanisms are collectively referred to as the immune system. Vaccines mimic and sometimes improve on the protective response normally mounted by the immune system after an actual infection. The great advantage of immunisation over natural infections is that immunisation has a much lower risk of adverse outcomes (see Box 2 and Questions 3 and 4).

Immunisation harnesses the body’s own defence mechanisms

To understand how immunisation protects against the diseases produced by pathogens such as viruses and bacteria, we first need to understand how the immune system works.

The immune system consists of trillions of specialised blood cells, known as white blood cells, and their products, such as antibodies. These cells are located throughout the body, not only in the bloodstream, but also in lymph glands, the spleen, the skin, lungs and intestine.

The skin and the lining of the lungs and intestine are the first line of defence against infection. These tissues and the white blood cells located at these sites form the innate immune system (see Figure 1.1). The white blood cells of the innate immune system (or guardian white blood cells) detect the presence of infection using sensors on their surfaces that recognise parts of pathogens or the toxins released by them. These fragments from pathogens or toxins are collectively known as antigens (see Question 2).

When guardian white blood cells detect the presence of pathogens, a second set of white blood cells (called lymphocytes) is activated (see Figure 1.1). Lymphocytes are categorised into two types: B-cells and T-cells.

T-cells respond to infections by releasing chemicals called cytokines, which trigger protective inflammation. Furthermore, T-cells can help combat pathogens by killing cells that harbour a pathogen hidden inside them. B-cells, sometimes with help from T-cells, make antibodies, which are complex proteins that attach in a ‘lock-and-key’ fashion either to pathogens or to the toxins released by them. When antibodies attach to a pathogen, they flag it for destruction, and when they attach to a toxin, they neutralise its ability to cause damage.
The human immune system:

All blood cells originally come from the bone marrow. There are three main cell types in our blood: red blood cells, which carry oxygen to our tissues; platelets, which help the blood clot; and white blood cells (leucocytes), which are the main component of the human immune system. There are two main types of leucocytes: guardian cells responsible for innate immunity and lymphocytes responsible for specific immunity.

The guardian cells of the innate immune system form the first line of defence against infection and can digest pathogens or vaccine particles and use these to activate lymphocytes. In addition, they produce chemicals capable of causing inflammation and amplifying specific immunity. These cells are the target of adjuvants in vaccines (Questions 2 and 3).

Lymphocytes have receptors for one antigen; that is, they are antigen specific. After infection or vaccination, specific lymphocytes recognise their target antigens, multiply and turn into short-lived effector cells or long-lived memory cells. Lymphocytes (T- and B-cells) have receptors on their surface for one particular antigen; that is, they are antigen specific.

In most cases, the outcome of these immune responses is termination of the infection followed by repair of any associated damage to the body’s tissues. However, some infections outstrip the immune system’s capacity to respond, leading to disease and sometimes death. By giving a vaccine before exposure to the infection, such serious outcomes can be avoided through generation of protective immunity in advance.

Immunisation is disease-specific

A healthy immune system has the capacity to generate hundreds of millions of T- and B-cells, each of which targets one particular antigen. Consequently, healthy people have the capacity to mount a protective response to essentially every infection they could possibly encounter during their lifetimes.

However, pathogens have evolved to overcome this defence and can sometimes overwhelm the immune response. Vaccines give the immune system a head start, providing valuable early protection against aggressive pathogens.

The specificity of these immune responses is the reason we need to have a separate vaccine for each disease. The capacity of the immune system to respond independently to each micro-organism in the environment also explains why the system cannot be ‘overloaded’ or damaged by giving the full range of currently available vaccines or by having multiple antigens in one vaccine preparation.

Vaccines harness the immune system’s capacity for memory

When a pathogen is recognised by the immune system, individual lymphocytes not only make antibodies and cytokines against the infection, but also multiply quickly. As a result, the number of lymphocytes (T- and B-cells) specific for that infection increases greatly, enabling the body to fight the infection more efficiently. Most of the cells involved in immune responses live for only a few days as effector cells, but a small number of lymphocytes survive for months or years after the infection has been cleared and retain a ‘memory’ of the invading pathogen. In the case of
BOX 2 / IS IT BETTER TO GET THE DISEASE THAN BE VACCINATED?

No, it is not better to get the disease than be vaccinated. The benefits of being vaccinated far outweigh those of infection with the pathogen. The rates of complications, both short- and longer-term, are much higher and generally more severe after natural infections than the rates of side effects associated with the corresponding vaccines.

For example, one in 15 patients with diphtheria die from the disease, whereas serious side effects from the diphtheria vaccine are very rare. Similarly, approximately one in four patients chronically infected with hepatitis B will die from cirrhosis of the liver (a severe, chronic inflammatory condition) or from liver cancer; this risk is reduced to almost zero after hepatitis B immunisation.

Vaccines have the added advantage of offering more effective protection against subsequent exposure to certain pathogens. Examples of diseases that do not always generate protective immunity include tetanus and whooping cough. In the case of tetanus, the tiny amount of toxin needed to produce life-threatening disease is too small to generate sufficient levels of protective antibodies to neutralise the toxin. To achieve protective antibody levels, it is necessary to give a much larger dose of toxin, which requires the use of the corresponding inactivated toxoid (see Question 2).

Left: Antibodies (orange) latch on to viruses (green). Each antibody recognises a specific antigen, or component of a pathogen, such as a bacterium or virus.
Infant vaccines work with the newborn immune system

The body’s immune system begins developing before birth. In the period during and soon after birth, when the functions of the immune system are still maturing, newborns are protected against many, but not all, serious infections by antibodies from their mothers (maternal antibodies). This protection usually lasts for about four months.

These maternal antibodies cross the placenta into the baby’s circulation before birth and are present in the mother’s breast milk. If the mother has been vaccinated recently or has recovered from infection during pregnancy, the amount of antibody transmitted to the baby can be sufficient to ensure complete protection. On the other hand, if the mother’s infection (particularly with the pathogen that causes whooping cough) or immunisation occurred a long time ago, the antibody levels may be lower and protection suboptimal.

The current immunisation programs are designed to balance the capacity of the baby’s immune system to respond to the vaccine, against the risk of infection. In the case of hepatitis B, for example, exposure to the virus at birth can result in the infant becoming a chronic carrier of infection more efficiently, without leading to the unwanted and serious complications that can be associated with infection in non-immune people (see Box 2).

A successful vaccine, like the corresponding infection, can harness the immune system’s memory capability by generating a population of long-lived lymphocytes (T- and B-cells) that are specific for the targeted pathogen. Again, the result is long-term protection against subsequent exposures to that pathogen and avoidance of the complications associated with a natural infection.

Passive immunisation provides immediate protection

Most vaccines work by actively switching on the recipient’s own immune system to make the antibodies and memory cells needed to provide long-term protection against infection. Such ‘active immunity’ is the primary goal of all immunisation programs.

However, this kind of active immune response takes 7–21 days to develop fully. Consequently, in the case of overwhelming infections, there is sometimes a role for ‘passive’ immunisation, which involves giving pre-formed antibodies obtained from healthy blood donors, as these can act much more quickly.

**Figure 1.2 / Effect of giving booster doses of vaccines:** After first immunisation of a non-immune person, a small and brief response occurs. When second (booster) doses are given, memory lymphocytes created during the initial response are switched on to generate a much more rapid and longer lasting protective response. This figure shows the levels of antibodies from B-cells after first and booster vaccinations. A similar, more effective memory response is also a property of T-cells.
What is in a vaccine?

**Vaccines contain antigens and adjuvants**

Vaccines generally have two major types of ingredients, antigens and adjuvants. Antigens are designed to cause the immune system to produce antibodies and/or T-cells against a specific pathogen or its toxin. Adjuvants amplify immune responses more generally.

**Disease-specific vaccine ingredients are called antigens**

Pathogens (such as viruses and bacteria) are assembled from building blocks—proteins, sugars, nucleic acids (such as DNA) and fats. Each pathogen has a unique set of these building blocks. Some can be recognised by the body’s immune system and are termed antigens. The antigens used in a vaccine are designed to trigger a specific protective response by the immune system to a particular pathogen. Therefore, each vaccine contains a different set of antigens.

**Several types of antigen are used in vaccines**

Some vaccines comprise the killed whole pathogen that the vaccine is designed to protect against. The virus or bacterium is grown in the laboratory and killed by heat and/or chemicals to render it non-infectious. The injectable poliomyelitis (polio) vaccine and inactivated hepatitis A vaccine are examples of this type of vaccine.

Other vaccines contain only components of the pathogen as their antigens. These components can be prepared by purifying them from the whole bacterium or virus, or by genetically engineering them. Engineered vaccines include the hepatitis B virus vaccine and the human papillomavirus vaccine, which protects against cervical cancer.

In some vaccines, sugar components of the pathogen are joined with proteins to create an antigen that can generate a stronger response—this allows even 6-week-old babies to make significant amounts of antibody, which they otherwise could not do until they are older. These vaccines are called conjugate vaccines, and include those against meningococcal and pneumococcal disease.

Another group of vaccines is based on the toxin produced by the pathogen that causes the disease symptoms. The toxin is chemically treated to make it into a harmless toxoid. The antibodies produced against this toxoid are still able to neutralise the toxin, and to prevent disease symptoms from developing. Examples of this type include the tetanus and diphtheria vaccines.

**Some vaccines contain live organisms**

Some vaccines contain an infectious microorganism. These are called live vaccines. The micro-organism may be derived from the pathogen (bacterium or virus) that the vaccine aims to protect.
against. This is usually achieved by growth of the pathogen in the laboratory under conditions designed to weaken or ‘attenuate’ it. This attenuation process permanently alters the pathogen so that it is still infectious, but is unable to cause the disease. Examples include the injectable MMR vaccine, the oral polio vaccine, and the chickenpox vaccine.

Alternatively, a live vaccine may consist of a naturally occurring organism that is closely related to the pathogen, but does not cause disease in healthy humans with intact immune systems. An example is the BCG vaccine against tuberculosis and leprosy.

Vaccines containing live pathogens are not recommended for people whose immune systems are impaired due to use of immunosuppressive drugs, serious illness or genetic abnormalities of the immune system because of the risk of causing disease. Similarly, live vaccines are not recommended during pregnancy as a precautionary measure, in case the pathogens they contain cross the placenta. This is because a baby’s immune system is not completely developed until after birth (see also Box 11, Question 4). Vaccines without live micro-organisms (‘killed’ vaccines), in contrast, are not harmful in pregnancy.

**Adjuvants amplify the immune system’s response**

Adjuvants are substances that promote a more vigorous immune response to vaccine antigens. They can also help target the body’s response. In doing so, they may cause mild local reactions (soreness, redness and swelling) at the injection site. These reactions are a healthy indicator of the strength of the underlying immune response.

Most killed vaccines incorporate adjuvants, to make the body’s defences think a significant infection is present. They stimulate stronger, longer-lasting immune responses to the vaccine antigens, leading to better protection against subsequent infection. Adjuvants are not needed in vaccines based on live organisms, as these naturally produce inflammation and amplify protective immunity.

In most human vaccines that contain adjuvants, the adjuvant is an aluminium salt (known as alum), which has a track record of safety dating back to the 1950s. Some newer vaccines incorporate more active adjuvants, derived from naturally occurring oil in water emulsions, fats from bacterial cell walls, or sugars. These can produce more vigorous and better targeted immune responses against the infectious agent.

**Vaccine quality is carefully monitored**

In addition to adjuvants and antigens, vaccines can contain minute quantities of materials from the manufacturing process. These can include trace amounts of detergents, nutrients from the laboratory cultures (see Box 4 and Box 6), chemicals used to kill the pathogens, stabilisers like gelatin or small amounts of DNA (see Box 5) and parts of dead organisms.

Vaccine developers are required by regulatory authorities to test for the presence of these extra materials during the manufacturing process to ensure they do not exceed levels known to be safe (see Question 4).

Occasionally, individuals can be allergic to an ingredient of a vaccine, although such reactions are rare. Fewer than one in 100,000 vaccine doses delivered cause a significant allergic reaction (see Box 6). /
Who benefits from vaccines?

Individuals benefit, in the short and long term

An effective vaccine protects an individual against a specific infectious disease and its various complications. In the short term, the efficacy of a vaccine is measured by its capacity to reduce the overall frequency of new infections, and to reduce major complications, such as serious tissue damage and death.

All vaccines currently in use in Australia confer high levels of protection that are sufficient to prevent disease in the great majority of vaccinated individuals, and in the wider community (see section on the community at large, right). In other countries where the use of vaccination is widespread, there has been a dramatic reduction in the number of people who become ill and die from formerly common and severe infections (see Box 7 and Figure 3.1). For example, the whooping cough vaccine prevents disease in 85% of recipients, while the measles vaccine prevents disease in 95% of recipients. The remaining individuals may not be fully protected and remain at least partially susceptible to infection. This may be due to genetic factors, or to the presence of other medical conditions that impair the capacity of the vaccine recipient to mount a protective immune response.

Booster doses of some vaccines are required to maintain protection. Examples include the whooping cough, tetanus, and polio vaccines, as well as the more recently introduced conjugate pneumococcal and meningococcal vaccines (see Question 2). In contrast, a single course of others, such as the hepatitis B vaccine, appears to be sufficient to provide lifelong protection.

Vaccines can protect against long-term complications of infections

The efficacy of vaccines is most often thought of in terms of their capacity to protect against the immediate consequences of serious diseases such as meningitis, pneumonia, hepatitis, chickenpox and measles. By preventing
infection, vaccines can also prevent long-term complications associated with chronic infections, where the pathogen persists in the body after the initial infection has passed.

Certain viruses can cause dormant infections. Such persistent infections can eventually lead to chronic damage of infected organs (e.g. encephalitis induced by measles, called SSPE, or cirrhosis of the liver, caused by hepatitis B or hepatitis C virus infection).

Persistent viral infections can also lead to late complications, including cancer and shingles. Viruses known to cause cancer and for which vaccines are available include hepatitis B and the human papillomavirus (HPV). Hepatitis B can lead to liver cancer and liver damage, whereas HPV can cause cervical and anal cancers. At present there is no protective vaccine available against hepatitis C infection; however, drug treatment is now effective in curing the disease in around 95% of cases at the two-year mark.

On the other hand, currently available vaccines are generally not capable of eliminating a virus infection once it has been acquired. This is why hepatitis B vaccine is administered from birth, and why HPV vaccine is delivered in late childhood or very early adolescence, before the individual is at risk of being exposed to the virus through sexual encounters.

An exception to the rule of vaccines being unable to control established viral infections is seen with the chickenpox vaccine. This vaccine protects against the development of a long-term complication of the infection, shingles (also known as herpes zoster). Shingles is a debilitating condition characterised by the appearance of painful blisters on parts of the skin above nerves where the chickenpox virus has lain dormant since infection in childhood. Adults who had chickenpox in childhood can be given a high-dose chickenpox vaccine to boost

---

**BOX 7 / ARE REDUCTIONS IN INFECTIONS DUE TO BETTER HEALTH AND HYGIENE RATHER THAN VACCINATION?**

Yes and no. Improvements in healthcare, such as widespread availability of antibiotics and better overall medical support systems, have reduced deaths from all diseases. However, the additional impact of vaccines themselves on infectious diseases is dramatically illustrated by the disappearance, or near disappearance, in Australia of deaths from diphtheria, whooping cough, tetanus, polio and measles (see Figure 3.1) and more recently from cases of Haemophilus influenzae type B (Hib) and meningococcal type C infection (see Figure 3.2).

For diphtheria, the death rate fell after the toxoid vaccine became available. In the case of diseases such as whooping cough, tetanus and measles, although there was some evidence of a decline in death rates before the relevant vaccines were available, the decreases in disease and death rates were much greater after introduction of the respective vaccines.

In contrast, improvement in hygiene, in the absence of vaccination, had a significant adverse impact on the incidence of polio. By lessening the chance of exposure of young people to the polio virus, the initial effect of improved hygiene was a steady increase in deaths. This is because paralysis and death were more common among older people who had not been exposed to polio during childhood. After the vaccine became available in Australia in the mid 1950s, the disease almost disappeared over the next decade. The introduction in 1993 of the Hib vaccine and in 2004 of the meningococcal type C vaccine, led to a very rapid and obvious decline in the number of severe and sometimes fatal infections. Such a dramatic effect in recent times could not possibly be attributed to any change in living conditions or medical treatment.
immunity, resulting in a substantial reduction in their subsequent risk of developing shingles.

**The community at large benefits**

An important feature of immunisation is that it brings benefits not only for the individual who receives the vaccine, but also for the entire population through a phenomenon called herd immunity. Herd immunity occurs when a significant proportion of individuals within a population are protected against a disease through immunisation. This situation offers indirect protection for people who are still susceptible to the disease, by making it less likely that they will come into contact with someone who is carrying the pathogen.

In addition to protecting unvaccinated individuals, herd immunity benefits the small proportion of people who fail to respond adequately to vaccination. In the case of a highly infectious disease such as measles, more than 95% of the population must be vaccinated to achieve sufficient herd immunity to prevent transmission if the disease recurs.

For other childhood infections, the proportion of the population that need to be vaccinated is lower, because the diseases are less infectious—for instance, until very recently no cases of diphtheria had occurred in Australia since the 1970s, despite immunisation coverage of much less than 95% of the population.

The effectiveness of herd immunity is well illustrated by reference to the introduction of a new form of the pneumococcal vaccine, which protects against disease caused by the bacterium *Streptococcus pneumoniae*. In addition to protecting susceptible infants and young children from the disease, this vaccine also reduces circulation in the community of the bacteria present in the vaccine. Consequently, older people are also protected, even though they have not been vaccinated against this organism (see Figure 3.2).

**Vaccines can control, eliminate and eradicate diseases**

When a large proportion of a community is immunised, it can lead to a situation where there are very low levels of the disease in that population. This is referred to as control of the disease. Even more effective and prolonged vaccination programs can result in interruption of transmission in the population for long enough to ensure that there is no residual disease—elimination of disease. However, even when high levels of community coverage with a vaccine are achieved, infection may be reintroduced, for example by unvaccinated travellers or, for some pathogens, an animal that is a carrier. In Australia, isolated outbreaks of infectious diseases such as measles have been attributed to transmission from unvaccinated carriers.

Once a high degree of control is achieved worldwide, it is theoretically possible to eradicate an organism and the associated risk of infection, provided there is no other animal that can carry the infection and transmit it back to humans. This was achieved with smallpox in the 1970s and there is hope that such a goal may also be achievable for polio and measles, for which, as for smallpox, humans are the only host. Compared with 350,000 cases in 1988, only 650 polio cases were reported worldwide in 2011, a figure that now stands at less than 150 for 2015. The only countries in which transmission of polio has never been interrupted are Nigeria, Pakistan and Afghanistan.

**Vaccination brings economic benefits**

Cost-effectiveness of community immunisation programs is determined by measuring the benefits—in terms of cost and quality of life—that result from preventing illness, disability and death, and comparing them with the costs of vaccine production and delivery to the population. A striking example is the benefits of polio vaccination. In the first six years after introduction of the vaccine, it was calculated that more than 150,000 cases of paralytic polio and 12,500 deaths were prevented worldwide. This represented a saving of more than US$30 billion annually in 1999 dollars.
Are vaccines safe?

Benefits of vaccines outweigh the risks

Vaccines, like other medicines, can have side effects. However, all vaccines in use in Australia provide benefits that greatly outweigh their risks.

Most reactions from vaccination are minor

The great majority of side effects that follow vaccination are minor and short-lived. The most common side effects for all vaccine types are ‘local’ reactions at the injection site, such as redness or swelling, which occur within hours and are clearly caused by the vaccine. More general or ‘systemic’ reactions, such as fever or tiredness, can also occur after vaccination, but careful studies have shown that they are much less common than local reactions.

Local reactions are outward signs that the vaccine is interacting with the immune system to generate a protective response. The nature of these reactions varies, depending on the type of vaccine given.

For example, if a person develops a fever due to an inactivated vaccine, they almost always do so within 24 to 48 hours—the time when the immune system is making an immediate response to the components of the vaccine. In contrast, the onset of fever caused by a live attenuated vaccine, such as the MMR vaccine, is delayed for seven to 12 days because this is the time needed for the attenuated virus in the vaccine to multiply sufficiently to induce a protective response from the immune system.

Some adverse events coincide with, but are not caused by, vaccination

Symptoms such as fever, rashes, irritability and nasal snuffles are common, especially among children. Consequently, it can be difficult to determine how many of these reactions are caused by a vaccine when the ‘background rate’ (how often it occurs anyway) in the same age group is unknown.

In some cases, these kinds of reactions may be caused by the vaccine. But in other situations, the symptoms may be unrelated, occurring by chance at the same time as the vaccination. For this reason, scientists refer to these kinds of symptoms as adverse events following immunisation to indicate that events that follow vaccination may not be caused by the vaccine.

One unique study from Finland addressed this issue. Researchers analysed common symptoms in 581 pairs of twins after one twin received the MMR vaccine and the other was given a dummy vaccine (a placebo). Between one and six days after the injection, the number of adverse events in the twin who received the MMR vaccine was almost identical to those in the twin who received placebo (see Figure 4.1). Between seven and 12 days after the injection, the vaccinated group had

BOX 8 / DOES THE MMR VACCINE CAUSE AUTISM?

Medical conditions with unknown causes have been incorrectly linked to particular vaccines. The most prominent example is the claimed link between the MMR vaccine and autism—a condition for which first clinical signs commonly occur in the second year of life, at a time when MMR vaccine is usually given.

The original suggestion that the MMR vaccine might be linked to autism was made in 1998, when a research group proposed that the attenuated (live) measles virus in the vaccine infected the intestine. The leader of the research group claimed this led to inflammation that resulted in lower absorption of nutrients needed for normal brain development, the outcome being developmental conditions such as autism.

Many comprehensive studies subsequently ruled out this suggested link by showing conclusively that rates of autism are the same among children who have and have not been vaccinated. Ultimately, the original report was shown to be fraudulent, and was retracted by the medical journal that published it.

Similarly, any link between thiomersal, which was previously used in minute quantities as a preservative in vaccines, and autism has also been excluded (see Question 2).
a measurable increase in symptoms that are known to be associated with administration of the attenuated measles vaccine, such as fever, irritability and rash. On the other hand, no difference between the two groups could be detected over that period in the frequency of cough- and cold-like symptoms—which occur commonly with or without vaccination. Moreover, even some of the symptoms known to occur after MMR vaccine were also seen in the group who received placebo, but at a lower rate.

In summary, this valuable study showed that many common symptoms that occur after a vaccine is given are not caused by the vaccine, but occur by chance at that time.

However, safety surveillance systems in countries like Australia require health care providers to report adverse events that occur following vaccination regardless of the cause. The reports are compared with historical trends to identify any changes that require special investigation and to assess whether adverse events are vaccine-related. For example, new vaccines are often reported more often than old vaccines, and reported events decrease as health carers gain familiarity with the vaccine. It can be misleading to rely on the reported raw numbers of adverse events, as a number of factors must be taken into account to determine if an event is coincidental or caused by the vaccine. The vast majority of adverse events are coincidental.

**Serious side effects from vaccines are extremely rare**

Potentially serious side effects, such as transient febrile seizures, have been reported after vaccination. However, such severe side effects occur much less often with the vaccine than they would if a person caught the disease itself.

This is well illustrated in young children by comparing the frequency of adverse events from the MMR vaccine with receiving influenza vaccine, whereas around nine in 10 children develop a fever after a proven influenza infection. The frequency of side effects associated with some earlier vaccine preparations (no longer in use in developed countries such as Australia) was higher than with the current generation of vaccines. Lastly, some alleged links between administration of certain vaccines and onset of diseases, particularly when the causes are unknown, have proven to be unfounded (see Boxes 8, 9 and 10).

---

**Figure 4.1** / Comparison of common symptoms in a paired twin study, where one twin received an MMR vaccine and the other received a placebo.

**Figure 4.2** / Severe complications due to MMR vaccine and measles among 1 million children aged under 5 years.
**BOX 9 / DO VACCINES CAUSE AUTOIMMUNE DISEASES?**

Over the past 30 years, the number of people who develop autoimmune diseases has been increasing, particularly in societies where rates of infectious disease have declined. This has raised the question of whether vaccine use is contributing to the reported rise in certain autoimmune disorders. With the exception of the two rare diseases mentioned below, the answer is no (see also Box 3). This conclusion is based on the stringent monitoring procedures put in place for detecting side effects of vaccination (see Question 5).

The first exception is the small increase in risk of developing the rare condition known as idiopathic thrombocytopenic purpura (ITP), which has been reported after the MMR vaccine. In this condition there is a short-term reduction in the number of small blood cells called platelets, which can lead to an increased risk of bleeding. However, the risk of developing this disorder associated with measles infection itself is more than 10 times greater than that associated with the vaccine (see Figure 4.2). The other exception is Guillain–Barré syndrome (see Question 5)—but again, the risk of developing the disease after influenza vaccination is much lower than after the actual infection.

**BOX 10 / DO VACCINES CAUSE ALLERGIC DISEASES?**

Like autoimmune diseases (see Box 9), allergic diseases such as asthma have become more common in the developed world over the past 30 years. However, there is no significant evidence that vaccines cause allergic diseases in otherwise healthy people.

A more meaningful question to ask is whether vaccines can precipitate attacks of serious allergic reactions in susceptible children or adults. Overall, the rate of severe allergic reactions following vaccination is extremely low, between 0.02 and 4.52 per 100,000 doses (see Figure 4.2). Nevertheless, precautions should always be taken by people with a past history of reaction to a specific vaccine or a strong family history of allergic disease. More information about vaccination of egg-allergic children was provided in Box 6 (Question 2).

Injectable vaccines used in Australia do not contain detectable amounts of antibiotics such as penicillin or sulphonamides to which some people may be allergic. The hepatitis B vaccine is grown in yeast. Although there have been some isolated reports of possible severe allergic reactions to this vaccine, supporting evidence is incomplete and the benefits of receiving the vaccine far outweigh the multiple risks associated with the infection.

**BOX 11 / IS VACCINATION DURING PREGNANCY SAFE, AND IF SO FOR WHAT DISEASES?**

It is safe to give inactivated vaccines in pregnancy. The rates of side effects among pregnant women are similar to those in the general population, and no link has been established between vaccination with inactivated vaccines in pregnancy and birth defects. The use of inactivated vaccines in pregnancy is particularly desirable for infections, such as influenza, that affect pregnant women or their babies more frequently and severely than the general population. This is because vaccination during pregnancy not only protects the mother against infection, but also provides protection to the unborn baby as a result of transfer of maternal antibodies (see Question 1).

Live attenuated vaccines, such as MMR or varicella vaccines, are not recommended during pregnancy, as the live viruses could in theory be transmitted from pregnant mother to their foetus. However, there is no evidence of an increased incidence of birth defects in children whose mothers inadvertently received live attenuated vaccines while pregnant.
How are vaccines shown to be safe?

Safety testing is an integral component of vaccine development and use

Careful testing of safety is an essential part not only of vaccine development and manufacture, but also of ongoing surveillance programs after vaccines have been introduced into the community.

The importance of strict routine testing is illustrated by an incident that occurred in 1955, before such testing was introduced, when a batch of polio vaccine had not been fully inactivated and still contained live virus. As a result, some recipients and their close family members developed polio infections, leading to paralysis and some deaths. No such events have been reported since.

Vaccine safety is always assessed before licensing for use

During vaccine development, initial safety testing procedures occur in two stages (see Figure 5.1). The first stage involves preclinical assessment in the laboratory. If a vaccine fails these safety tests, it cannot progress into clinical trials. Vaccines are then evaluated in three phases of clinical trials. In phase I clinical trials, the vaccine candidate is given to small numbers (25–50) of healthy adults with the primary goal of assessing safety.

Phase II trials involve hundreds of participants and are designed to demonstrate how effective a vaccine is in mounting an immune response, and to determine the optimal dose regimen. Phase III clinical trials aim to demonstrate protection against the target disease and safety, and this usually requires administration of the vaccine to many thousands of potentially susceptible people. Only after the vaccine has passed each of these safety and
Withdrawal of vaccines from the market is very rarely required. Occasionally, adverse events may occur too infrequently to be detected during phase III trials. For example, rotavirus is a viral infection that causes severe diarrhoea among infants and young children. One specific vaccine against rotavirus called Rotashield was shown to be effective and generally well tolerated in clinical trials. A few cases of intussusception, a blockage of the small bowel, were noted during a phase III trial but the numbers were not found to be statistically significant. As a normal precaution, doctors were then encouraged to report cases of intussusception when Rotashield was introduced. Within a year this reporting revealed a small but significant increase in the number of cases of intussusception, leading to withdrawal of the vaccine. Rotavirus vaccines were redeveloped and further tested in clinical trials sensitive enough to rule out the risk of intussusception at the level reported following use of the Rotashield vaccine. When the new vaccines were introduced, active surveillance in Australia detected a slightly higher number of cases of intussusception. When the risk was balanced against the benefits of the vaccines, which prevent an estimated 1–2 deaths and nearly 8,000 hospitalisations each year in Australia, continued use was recommended. Similarly, the World Health Organization, based on the benefits of new rotavirus vaccines greatly exceeding the risk of intussusception, has recommended continued use globally.

**Box 12** / If vaccines are so rigorously tested, why are some withdrawn from the market after introduction into the community?

Withdrawal of vaccines from the market is very rarely required. Occasionally, adverse events may occur too infrequently to be detected during phase III trials. For example, rotavirus is a viral infection that causes severe diarrhoea among infants and young children. One specific vaccine against rotavirus called Rotashield was shown to be effective and generally well tolerated in clinical trials. A few cases of intussusception, a blockage of the small bowel, were noted during a phase III trial but the numbers were not found to be statistically significant. As a normal precaution, doctors were then encouraged to report cases of intussusception when Rotashield was introduced. Within a year this reporting revealed a small but significant increase in the number of cases of intussusception, leading to withdrawal of the vaccine. Rotavirus vaccines were redeveloped and further tested in clinical trials sensitive enough to rule out the risk of intussusception at the level reported following use of the Rotashield vaccine. When the new vaccines were introduced, active surveillance in Australia detected a slightly higher number of cases of intussusception. When the risk was balanced against the benefits of the vaccines, which prevent an estimated 1–2 deaths and nearly 8,000 hospitalisations each year in Australia, continued use was recommended. Similarly, the World Health Organization, based on the benefits of new rotavirus vaccines greatly exceeding the risk of intussusception, has recommended continued use globally.

**Safety assessments continue once a vaccine is licensed for use**

Some side effects of vaccines are so uncommon, they are not detected during the extensive safety testing before vaccine licensure. To ensure that authorities can detect such unanticipated side effects, careful surveillance continues even after a vaccine candidate has proven to be effective and has passed all safety checks in thousands of people. The formal term for this systematic collection of data and analysis of reports of any suspected adverse events is post-licensure assessment (see Figure 5.1).

The value of ongoing safety testing of licensed vaccines is demonstrated by the successful identification of potential clinical problems. The most recent example is the detection of an increased risk of febrile seizures that unexpectedly occurred in young children given a particular influenza vaccine in Australia in 2010. When the problem first became apparent, the use of all influenza vaccines in young children was suspended to allow time for authorities to identify the one type of vaccine preparation causing the problem. Meanwhile, influenza vaccines shown not to be associated with unacceptable rates of febrile seizures were reintroduced to ensure that protection against influenza remained available for children at high risk of complications from the disease.

Likewise, in adults, long-term surveillance has been used to determine the risk of developing Guillain–Barré syndrome (GBS), a rare (one to two cases per 100,000 people) but serious condition characterised by temporary paralysis which has occasionally been reported to occur after influenza vaccination. The conclusion of these long-term studies was that, at most, one additional case of GBS occurs for every million people vaccinated against influenza. On the other hand, the risk of developing GBS after influenza infection is much greater. /
The benefits of vaccination worldwide will continue

Vaccination represents the most successful form of disease prevention available today. In the past 20 years, vaccine technology has improved, resulting in production of vaccines against a broad range of infectious diseases.

Nevertheless, the burden of infectious diseases worldwide remains high, particularly in developing countries.

According to the World Health Organization, infections still account for about 40% of all recorded deaths worldwide.

Future strategies to meet this challenge include extending the use of existing vaccines, new technologies to deliver vaccines and generating new vaccines. Priority targets for future vaccines include viruses, bacteria and parasites (see Figure 6.1).

Existing vaccines will be used in new ways

Using existing vaccines in different ways shows promise. One example is administration of a killed vaccine, normally given during childhood, to a pregnant woman. This immunisation boosts antibody levels in the mother, allowing the extra antibodies to reach her baby by crossing the placenta, and via the mother’s breast milk. Doing this protects her newborn baby while the baby’s immune system is still maturing.

In the future, giving a malaria vaccine in this way could be beneficial to protect newborns from becoming chronically infected from birth. Another way of applying existing vaccines more effectively is to target them to elderly people, who make up a growing proportion of the population. For instance, elderly people in hospitals are more prone to infections with vaccine-preventable diseases such as Streptococcus pneumoniae, influenza virus and shingles-causing varicella.
New technologies will change vaccine delivery

Many technologies under development will improve the simplicity and effectiveness of vaccine delivery.

To make a vaccine that only needs to be given once, it must either be very powerful, or be packaged in such a way that its contents are released intermittently once it has been administered. Under development are multilayer particle technologies and alternative adjuvants, which have the potential to remove the need for multiple shots.

Needle-free administration is already possible for some vaccines, such as live vaccines given orally (polio vaccine) or via a nasal spray (influenza vaccines). Currently, many vaccines need to be injected, but researchers are working on edible (plant-based) vaccine materials, needle free skin patches and microneedle injection technologies to get the vaccine through the skin without discomfort.

Technologies for delivering multiple vaccines in one injection are improving—many different killed vaccines can already be given in one injection without impairing the immune response to any of them, and some live virus vaccines can also be given together.

Novel vaccines

Most successful vaccines protect against acute infections largely through production of antibodies. Vaccines for chronic infections, in particular malaria, HIV and tuberculosis remain a problem. One of the major reasons for this is the viruses, bacteria and parasites that cause these infections ‘hide’ from the immune system in the person’s own cells. To overcome this, an immune response mediated by T-cells is required (see Question 1), instead of, or in addition to, an antibody response.

There are effective vaccines to target infections that predispose people to long-term complications, such as cancer. Examples include vaccines to the human papillomavirus (HPV), hepatitis B and the shingles-causing varicella virus. On the other hand, there are still no vaccines for other infections associated with many serious long-term complications. For instance, infection with the bacterium *Helicobacter pylori* predisposes patients to stomach cancer, group A streptococcus infection is responsible for rheumatic fever—still a major cause of death and disability in developing countries, and chlamydia infection can lead to infertility and blindness (see Figure 6.1).

Vaccines have the potential to be used to treat rather than prevent infectious and noninfectious diseases. Such therapeutic vaccines are being targeted at persistent infections, such as shingles, and also at non-infectious conditions, including autoimmune disorders, allergies and cancers not related to infections. In the case of tumours, the vaccine can either be directed against the tumour itself or be designed to amplify the anti-tumour immune response. By contrast, for autoimmune or allergic disorders, the vaccines are being designed to switch off unwanted immune responses, so-called negative vaccination—rather than switching on the useful immune response needed for infections and cancer.